Impact of low- and high-risk operators handling irinotecan on the blood contamination of health care workers in oncology day care units

• Published in: Journal of oncology pharmacy practice 2023-06, Vol.29 (4), p.905-911
• Main Authors: Pirot, C., Benoist, H., Lagadu, S., Delépée, R., Saint-Lorant, G.
• Format: Article
• Language: English
• Subjects: Adenomatous polyposis coli; Antineoplastic drugs; Antitumor agents; Blood; Caregivers; Contamination; Decontamination; Erythrocytes; Health care; Irinotecan; Life Sciences; Medical personnel; Medication; Metabolites; Mutagenicity; Oncology; Pharmaceutical sciences
• ISSN: 1078-1552; 1477-092X
• DOI: 10.1177/10781552221090965

Introduction Health care workers handling antineoplastic drugs (ADs) are at risk of mutagenicity and adverse reproductive effects. Despite protective equipment and AD handling guidelines, AD levels are still detected in caregivers in oncology units. This study attempted to assess blood contamination by irinotecan and its metabolites in all health care workers in oncology day hospital units according to activities specific to each employment category. Methods The study was performed at two different hospitals: a university hospital and a comprehensive cancer centre. Forty-four participants were categorized according to their daily activity as a high-risk operator (29 nurses/ward aides and 5 cleaning staff) and a low-risk operator (7 doctors and 3 secretaries). The collected blood samples were subjected to UHPLC–MS/MS. The plasma and red blood cell (RBC) levels of irinotecan and its metabolites (SN-38; APC) were determined using a validated analytical method detection test. Results Two hundred sixty-four assay results were collected (132 plasma results and 132 RBC results). The comparison between low- and high-risk operator-contaminated workers was not significant (18.33% positive results in low-risk operators vs. 25.98% positive results in high-risk operators; P = 0.22). This homogeneity showed overall contamination within the unit. Positive results were obtained in 21.43% of physicians, 11.11% of secretaries, 25.86% of nurses/ward aides and 26.67% of cleaning staff. These results could be explained by the lack or failure of personal and collective protective equipment. A lack of protection and inadequate decontamination procedures can result in surface contamination. Conclusions This study evaluated blood contamination with irinotecan and its metabolites in health care workers from day hospital care units. Among the 24.24% of contaminations observed in care units, the difference between low- and high-risk operator contamination was not significant (P = 0.22). The impact on blood contamination found is the same between low- and high-risk caregivers. This implies that the protective precautions associated with the handling of anticancer drugs must therefore be followed by all staff, including those believed to be at low risk of exposure.